The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
Open accessAbstract
Advanced gene and cellular therapies risk a second "valley of death" due to their high costs and low patient population. As these are life-saving therapies, measures are urgently needed to prevent their withdrawal from the market.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High costs involved in the production of cell-based therapies currently limit their use in the clinic.
“This, coupled with the high costs involved in the production of such cell-based therapies (192), is currently limiting their use in the clinic.”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [192]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regeneration of the entire human epidermis using transgenic stem cells
Hirsch, T., Rothoeft, T., Teig, N., Bauer, J. W., Pellegrini, G., De Rosa, L., Scaglione, D., Reichelt, J., Klausegger, A., Kneisz, D., et al. (2017) · Nature · doi:10.1038/nature24487 · Cited by 693
Flagged first, then by citations
Research works printed but not linked: 13
- Abbot A (2013) Italian stem‐cell trial based on flawed data. Nature https://doi.org/10.1038/nature.2013.13329 · DOI
- Aiuti A, Pasinelli F, Naldini L (2022) Ensuring a future for gene therapy for rare diseases. Nat Med 28: 1985–1988 · DOI
- Cossu G, Birchall M, Brown T, De Coppi P, Culme‐Seymour E, Gibbon S, Hitchcock J, Mason C, Montgomery J, Morris S et al (2018) Lancet commission: stem cells and regenerative medicine. Lancet 391: 883–910 · DOI
- Cossu G, Fears G, Griffin G, ter Meulen V (2020) Regenerative medicine: a long and winding road. Lancet 395: 1746–1747 · DOI
- Dal‐Ré R, Kesselheim AS, Bourgeois FT (2020) Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 323: 1903–1904 · DOI
- De Luca M, Aiuti A, Cossu G, Palmer M, Pellegrini G, Robey P (2019) Stem cells find their way to clinics. Nat Cell Biol 21: 801–811 · DOI
- Ferrua F, Aiuti A (2017) Twenty‐five years of gene therapy for ADA‐SCID: from bubble babies to an approved drug. Hum Gene Ther 28: 972–981 · DOI
- Halley MC, Smith HS, Ashley EU, Goldenberg AJ, Tabor HK (2022) A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States. Nat Genet 54: 219–222 · DOI
- Kueckelhaus M, Rothoeft T, De Rosa L, Yeni B, Ohmann T, Maier C, Eitner L, Metze D, Losi L, Seconetti AS et al (2021) Transgenic epidermal cultures for junctional epidermolysis bullosa – 5 – year outcomes. N Engl J Med 385: 2264–2270 · DOI
- McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F et al (2017) Ataluren clinical evaluator training group; ACT DMD study group. 2017. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD):a multicentre, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet 390: 1489–1498 · DOI
- Palamenghi M, De Luca M, De Rosa L (2022) The steep uphill path leading to ex vivo gene therapy for genodermatoses. Am J Physiol Cell Physiol 323: C896–C906 · DOI
- Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G (2010) Limbal stem‐cell therapy and long‐term corneal regeneration. N Engl J Med 363: 147–155 · DOI
- Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M et al (2017) Marketing of unproven stem cell–based interventions: a call to action. Sci Transl Med 9: eaag0426 · DOI
Cited by
Sorted by citations
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Metadata
- Authors
- De Luca, M., & Cossu, G.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Cossu, Giulio
- Venue
- EMBO Reports
- Published
- 2023-01-02
- Volume
- 24
- Issue
- 2
- Pages
- e56661-e56661
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC9900339
- OpenAlex
- W4313406630
- Cited by
- 35
- References
- 1
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 7
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- EMBO Reports (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by-nc-nd)
- Funders
- Medical Research Council (MR/S015116/1)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- cell and gene therapy, treatment costs, drug availability, market access, valley of death, rare diseases
- MeSH terms
- Environment, Humans, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
